Biopharma Investor ESG Communications Initiative
“A confirmation that we are on track with our strategic thinking on ESG.”
- Biopharma
A sector-focused direct dialog between biopharma and investors, complemented by engagement with key sector stakeholders.
The Challenge
The Biopharma Investor ESG Communications Initiative (the Initiative) was set up in mid-2018 to address the common interest of leading biopharma companies and investors in achieving more effective, efficient and decision-useful communications about the sector’s environmental, social, and governance (ESG) topics.
They also discussed the difficulties in determining the biopharma ESG topics, as well as the challenges about the ESG information companies should disclose and how it should be organized for effective communication with capital markets, especially at the sector level.
Consensus Oriented Dialog
The Initiative facilitates a sector-focused direct dialog between biopharma and investors, complemented by engagement with key sector stakeholders. The conversations seek to build understanding on the ESG topics specific to the sector, and provide useful insights to support biopharma companies in setting and implementing their individual ESG communications strategies with the investor community.
Over 150 executives from biopharma companies, investor organizations, as well as key stakeholder groups have engaged in discussions since 2018.
Forward-looking Resource
The Initiative insights are reflected in the Biopharma Investor ESG Communications Guidance, which has been updated every few years.
The Guidance is intended as a resource for biopharma, investors, as well as key sector stakeholders that would like to understand the biopharma sector’s ESG and sustainability landscape. It identifies the biopharma ESG topics of shared interest, and provides insights to inform strategic ESG communications. The Initiative and the Guidance acknowledges that each entity will need to adapt to their own unique strategy, business model and readiness.
Initiative Partners and Sponsors
Additional Participants
BeOne, Boehringer Ingelheim, Chiesi, Eli Lilly, Roche, Ferring, Hikma, Ipsen, Jazz Pharmaceuticals, LEO Pharma, Organon, Regeneron, Sanofi, Takeda, UCB
Get in touch to find out more
Ongoing Dialogs
“Since the Initiative launched, more than 150 executives from biopharma and investor companies have engaged in direct dialogs. Discussions with key stakeholder groups are ongoing, and the circle of contributors is expanding.”
BSRT Investor Network Participants
Thank you to everyone from the organizations that have contributed to the dialog.
